Clinical trials: Cancer of Liver
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
- Trial name
- METIV-HCC (NCT01755767)
- Testing
- Tivantinib
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 383 people
- Sponsor
- Daiichi Sankyo
Colorectal Cancer
A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid…
- Trial name
- NCT01383707
- Testing
- 5-Fluorouracil (5-FU), Bevacizumab, Levofolinic acid
- Where
- 11 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Cancer of the Liver, Liver Cancer
NOLA (NeuWave Observational Liver Ablation) Registry
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.
- Conditions
- Cancer of the Liver, Liver Cancer, Neoplasms, Liver
- Trial name
- NCT04107766
- Testing
- Microwave Ablation
- Where
- 28 sites in United States, China and 6 more
- Volunteers
- 1,254 people
- Sponsor
- Ethicon, Inc.
Carcinoma, Hepatocellular
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer.
- Trial name
- NCT00699374
- Testing
- sunitinib malate, sorafenib
- Where
- 171 sites in United States, Australia and 21 more
- Volunteers
- 1,075 people
- Sponsor
- Pfizer
Carcinoma, Hepatocellular
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
- Trial name
- NCT01246986
- Testing
- LY2157299, Sorafenib, Ramucirumab
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma (HCC)
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not…
- Trial name
- NCT03412773
- Testing
- Tislelizumab, Sorafenib
- Where
- 122 sites in United States, China and 9 more
- Volunteers
- 684 people
- Sponsor
- BeiGene
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow…
- Trial name
- NCT01894243
- Testing
- Olaparib tablet dosing
- Where
- 12 sites in Czechia, France and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of…
- Trial name
- HIMALAYA (NCT03298451)
- Testing
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2)
- Where
- 160 sites in United States, Brazil and 15 more
- Volunteers
- 1,324 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
This study will evaluate the safety, tolerability, pharmacokinetic and efficacy of fisogatinib (formerly known as BLU-554) in combination with CS1001 in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)
- Trial name
- NCT04194801
- Testing
- Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg, Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg, Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- CStone Pharmaceuticals
Liver Cancer
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00605722
- Testing
- bevacizumab (Avastin), erlotinib (Tarceva)
- Where
- 6 sites in Philippines, South Korea and 1 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
Hepatocellular Carcinoma
DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
The main objective is to evaluate the value of dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in prediction of response of patients with hepatocellular carcinoma (HCC) to treatment with Sorafenib assessed by…
- Trial name
- DCE-MRI (NCT01806740)
- Testing
- Gadoterate meglumine
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Guerbet
Carcinoma, Hepatocellular
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
- Trial name
- NCT00494299
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 75 sites in Japan, South Korea
- Volunteers
- 458 people
- Sponsor
- Bayer
Essential Fatty Acid Deficiency (EFAD)
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD).
- Trial name
- NCT02476994
- Testing
- Clinolipid, Intralipid
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baxter Healthcare Corporation
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
- Trial name
- MEDI-573-1028 (NCT01498952)
- Testing
- MEDI-573 (1 of 3 doses), Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- MedImmune LLC
Colon Cancer Liver Metastasis
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
The purpose of this study is to determine the safety and efficacy of Thermodox, a thermally sensitive liposomal doxorubicin, in combination with thermal ablation in the treatment of hepatic colorectal liver metastases (CRLM).
- Trial name
- ABLATE (NCT01464593)
- Testing
- Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Imunon